Hydrolysis of cefamandole nafate in dialysis patients.

Antimicrobial Agents and Chemotherapy
R L NielsenT Ozawa

Abstract

The hydrolysis of cefamandole nafate was examined in vivo in five dialysis patients and five subjects with normal renal function. The plasma half-life of cefamandole was prolonged in the patients with renal failure compared with normal subjects (18.3 +/- 4.5 [standard deviation] versus 10.35 +/- 1.4 min, P less than 0.01). The pharmacokinetics of cefamandole nafate best fit two-compartment, open-model kinetics. We conclude that patients with severe renal failure are capable of hydrolyzing cefamandole nafate to cefamandole and formate at a rate sufficiently rapid so as not to allow an accumulation of cefamandole nafate. The difference in half-life may be related to urinary excretion of cefamandole nafate in normal individuals.

References

Aug 1, 1976·Journal of Pharmaceutical Sciences·J M IndelicatoB J Cerimele
Jul 1, 1977·Antimicrobial Agents and Chemotherapy·J R TurnerJ S Wold
May 1, 1978·The Journal of Infectious Diseases·J S WoldR S Griffith
Aug 1, 1978·Computers and Biomedical Research, an International Journal·C Gomeni, R Gomeni
Mar 1, 1972·Antimicrobial Agents and Chemotherapy·W E Wick, D A Preston

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2021 Meta ULC. All rights reserved